Gilead Sciences (NASDAQ:GILD) Price Target Raised to $140.00 at Needham & Company LLC

Gilead Sciences (NASDAQ:GILD) had its target price upped by Needham & Company LLC from $133.00 to $140.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other reports. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research report on Friday, October 31st. Citigroup upped their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Finally, Truist Financial reiterated a “buy” rating and issued a $145.00 target price (up previously from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.13.

Gilead Sciences Stock Down 0.1%

GILD stock traded down $0.18 during midday trading on Thursday, hitting $125.02. The company’s stock had a trading volume of 6,599,193 shares, compared to its average volume of 7,965,889. The firm’s 50-day moving average is $117.24 and its 200-day moving average is $112.64. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company has a market cap of $155.11 billion, a PE ratio of 24.90, a P/E/G ratio of 0.81 and a beta of 0.32. Gilead Sciences has a 12 month low of $86.08 and a 12 month high of $127.68.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 94,646 shares of company stock valued at $11,311,286 in the last ninety days. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning boosted its holdings in shares of Gilead Sciences by 7.4% in the third quarter. Creative Planning now owns 303,062 shares of the biopharmaceutical company’s stock valued at $33,640,000 after acquiring an additional 20,975 shares during the period. SummitTX Capital L.P. grew its position in Gilead Sciences by 10.3% during the 3rd quarter. SummitTX Capital L.P. now owns 74,476 shares of the biopharmaceutical company’s stock worth $8,267,000 after purchasing an additional 6,928 shares during the last quarter. Zacks Investment Management increased its stake in Gilead Sciences by 1.3% in the third quarter. Zacks Investment Management now owns 453,585 shares of the biopharmaceutical company’s stock valued at $50,348,000 after purchasing an additional 5,616 shares during the period. Credit Agricole S A purchased a new stake in shares of Gilead Sciences in the third quarter valued at about $78,491,000. Finally, Raymond James Financial Inc. boosted its stake in shares of Gilead Sciences by 2.9% during the third quarter. Raymond James Financial Inc. now owns 1,815,811 shares of the biopharmaceutical company’s stock worth $201,556,000 after buying an additional 51,188 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.